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Abstract: Citrate is an intermediate in the “Tricarboxylic Acid Cycle” and is used by all aerobic
organisms to produce usable chemical energy. It is a derivative of citric acid, a weak organic acid
which can be introduced with diet since it naturally exists in a variety of fruits and vegetables, and can
be consumed as a dietary supplement. The close association between this compound and bone was
pointed out for the first time by Dickens in 1941, who showed that approximately 90% of the citrate
bulk of the human body resides in mineralised tissues. Since then, the number of published articles
has increased exponentially, and considerable progress in understanding how citrate is involved in
bone metabolism has been made. This review summarises current knowledge regarding the role of
citrate in the pathophysiology and medical management of bone disorders.
Keywords: bone metabolism; bone mineral density; bone remodelling; citrate supplement; osteopenia;
osteoporosis; kidney diseases
1. Introduction
Citrate is an intermediate in the tricarboxylic acid cycle (TCA cycle, Krebs cycle), a central
metabolic pathway for all aerobic organisms, including animals, plants, and bacteria [1,2]. In humans,
citrate is produced in the mitochondria after the condensation of acetyl coenzyme A (acetylCoA) and
oxaloacetate, which are catalysed by citrate synthase; it then enters the TCA cycle, thus becoming the
primary adenosine 5′-triphosphate (ATP) provider by which living cells harvest the energy they need
to accomplish essential and specific functions [1].
The intracellular citrate level reflects the energy status of the cell and acts as a regulator. When
the cellular ATP is abundant and the energy demand of the cells is low, the excess citrate can be
exported to the cytosol by means of a mitochondrial citrate carrier [3]. It can be used for the lipid
biosynthesis of highly proliferating cells [4] or for supporting the tissue-related functions of specialised
cells, including the mineralisation of the extracellular matrix by osteoblasts, the bone-forming cells [5].
In this regard, the close association between citrate and bone was pointed out for the first time by
Dickens in 1941 [6]. Since then, the number of published articles dealing with this topic has increased
exponentially (Figure 1), and considerable progress in understanding how citrate is involved in bone
metabolism has been made. This review summarises the current knowledge regarding the relationship
between citrate and bone pathophysiology, starting from the link with bone cells and the mineralised
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matrix, moving through the role of citrate in the onset of bone disorders, and concluding with a critical
evaluation of the clinical use of citrate supplements for the medical management of bone diseases.
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Figure 1. Distribution of the biomedical citations indexed by PubMed over seven decades (n = 949, 
from 1949 to 2018). The search query focused on "citrate" and "bone", with a search restricted to the 
terms "Title", "Abstract" or "Medical Subject Headings". Only citations related to studies on humans 
are included with the exception of those dealing with citrate as an anticoagulant. 
2. Citrate Homeostasis: General Physiological Concepts 
2.1. The Pillars of Citrate Homeostasis 
There is a balance between citrate availability and elimination, depending on physiological 
requirements. Basically, citrate homeostasis depends on four domains, i.e., nutritional intake, renal 
clearance, cellular metabolism, and bone remodelling (Figure 2). 
Citric acid is naturally contained in fruits and vegetables, particularly in citrus fruits, with 
concentrations ranging from 0.005 mol/L in oranges and grapefruit to 0.30 mol/L in lemons and limes 
[7,8]. Food citrate may also be produced biotechnologically by many microorganisms through a 
fermentation process, and of these, Aspergillum Niger has been recognised as the most efficient 
producer [9]. Industrial-scale citric acid is employed instead of fresh lemon juice in a variety of pre-
prepared meals, and it is also used as an additive in foods and beverages since it acts as a preservative, 
acidity regulator, flavoring substance and emulsifying agent. In fact, due to the variety of 
applications, citric acid is the most consumed organic acid in the world, leading to high commercial 
interest as well as motivating scientists to discover new super-producing techniques [10]. 
The usual nutritional intake of citrate is approximately 4 grams per day [11] and more than 95% 
of it is absorbed in the small intestine [12] by means of the sodium-dicarboxylate (NaDC) 
cotransporter similar to that described in the kidney [13]. The total daily consumption of citric acid 
may exceed 500 mg/kg of body weight, but considering the low citrate amount in foods, both those 
in which it is naturally contained and those in which it is added in artificial form, the ingestion of 
excessive doses is very unlikely [14]. 
Figure 1. Distribution of the biomedical citations indexed by PubMed over seven decades (n = 949,
from 1949 to 2018). The search query focused on “citrate” and “bone”, with a search restricted to the
terms “Title”, “Abstract” or “Medical Subject Headings”. Only citations related to studies on humans
are included with the exception of those dealing with citrate as an anticoagulant.
2. Citrate Homeostasis: General Physiological Concepts
2.1. The Pillars of Citrate Homeostasis
There is a balance between citrate availability and elimination, depending on physiological
requirements. Basically, citrate homeostasis depends on four domains, i.e., nutritional intake, renal
clearance, cellular metabolism, and bone remodelling (Figure 2).
Citric acid is naturally contained in fruits and vegetables, particularly in citrus fruits, with
concentrations ranging from 0.005 mol/L in oranges and grapefruit to 0.30 mol/L in lemons and
limes [7,8]. Food citrate may also be produced biotechnologically by many microorganisms through
a fermentation process, and of these, Aspergillum Niger has been recognised as the most efficient
producer [9]. Industrial-scale citric acid is employed instead of fresh lemon juice in a variety of
pre-prepared meals, and it is also used as an additive in foods and beverages since it acts as a
preservative, acidity regulator, flavoring substance and emulsifying agent. In fact, due to the variety of
applications, citric acid is the most consumed organic acid in the world, leading to high commercial
interest as well as motivating scientists to discover new super-producing techniques [10].
The usual nutritional intake of citrate is approximately 4 grams per day [11] and more than 95% of
it is absorbed in the small intestine [12] by means of the sodium-dicarboxylate (NaDC) cotransporter
similar to that described in the kidney [13]. The total daily consumption of citric acid may exceed
500 mg/kg of body weight, but considering the low citrate amount in foods, both those in which it is
naturally contained and those in which it is added in artificial form, the ingestion of excessive doses is
very unlikely [14].
The dietary ingestion of citrate is able to enhance the plasma level within thirty minutes; it is then
filtered at the glomerular level just as quickly, and eventually reabsorbed according to physiological
needs [15]. In healthy individuals, the serum concentration of circulating citrate is relatively constant,
ranging from 19 to 50 mg/L with an average of 20 mg/L [16,17]. Citrate in plasma exists as ≈95%
tricarboxylate, ≈4% dicarboxylate, and 1% monocarboxylate, and the majority is complexed to divalent
ions, such as calcium and magnesium. The high impermeability of the plasma membrane precludes the
cellular uptake of citrate from the extracellular fluid. Under special conditions, some cells (i.e., intestinal
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enterocytes and kidney tubular cells) express a plasma membrane citrate transporter belonging to the
“solute carrier” 13 family (Slc13, NaDC), which is essential for uptake from the gastrointestinal tract
and tubular fluid.Nutrients 2019, 11, x FOR PEER REVIEW 3 of 34 
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citrate is rapidly introduced into the circulation, filtered at the glomerular level, and eventually 
reabsorbed according to physiological needs. The citrate uptake from the extracellular milieu may 
occur only when specific transporter proteins are expressed, i.e., sodium-dicarboxylate (NaDC)1 
belonging to the “solute carrier” 13 (Slc13) family. The citrate produced by mitochondria only 
marginally contributes to citrate homeostasis, since it is almost all used by cells as an energy source, 
or for the synthesis of lipids and other specific functions, i.e., citration of the extracellular matrix by 
the osteoblasts. In fact, the bulk stored in bone is the main endogenous source of citrate which 
becomes available following the resorption of the mineralised matrix by the osteoclasts. The 
mitochondrial citrate-transport protein (CTP) is essential for the release of citrate from the 
mitochondria to cytosol. 
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almost all the mitochondrial production is consumed by cells as an energy source or for supporting 
specific cell functions [4,5]. Nowadays, it is well known that the main endogenous bulk of citrate is 
Figure 2. e fo r o ains of citrate ho eostasis. e las a level of citrate ainly depends on four
sources, i.e., nutritional intake, renal clearance, cellular metabolism, and bo e remodelling. Food citrate
is rapidly intro uced into the circulation, filtered at the glomerular level, and ev ntually reabsorbed
according to physiological needs. The citrate uptake from the extracellular milieu m y occur only
when specific tra sporter proteins a e ex essed, i.e., sodium-dicarboxylate (NaDC)1 belonging to the
“so ute carrier” 13 (Slc13) family. The citrate produced by mitochondria only marginally ontributes to
citrate homeostasis, since it is almost all used by cells as an energy so rce, or for the sy thesis of lipids
and ther pecific funct ons, i.e., ci ration of the extracellular matrix by the osteoblasts. In f ct, the
bulk stored in bone is the main endogenous source of citrate which becomes available following the
resorption of the mineralised matrix by the ste clasts. Th mitochondrial citra e-transport protein
(CTP) is essential for he release of citrate from the mitochondria to cytosol.
However, the net balance between gastrointestinal absorption and the urinary excretion of
citrate sugg sts that nutriti nal intake cannot be solely responsible for the maintenance of plasma
homeostasis [15,17]. The cellular metabolism also has a scarce impact on citrate availa ility since almost
all the mito ho drial production is consume by cells as an energy source or for supporting specific
cell functions [4,5]. Nowadays, it is well known that the main endogenous bulk of citrate is stored in
bone and is mobilised f llowing the resorpti n of the mineralised matrix b th osteoclasts [17].
2.2. Citraturia as A Marker of Citrate Homeostasis and Bone Health Status
As circulating itrate is freely filtered in the glomerulus, 24-h excretion i considered to be a
valid m rker for highlighting alterations of ci rate h meostasis [11]. The reference values for urinary
citrate levels range from 320 to 1260 mg/24 h, with an average in males of 550 mg/24 h and in females
of 680 mg/24 h [18,19]. The high r excretion f citrate in females is i relation to the estrogenic
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rate [20] and explains the lower incidence of nephrolithiasis in premenopausal women, considering
that citrate-calcium binding is one of the main mechanisms for inhibiting stone formation [21]. Based
on the reference values for lithogenic risk, the threshold for the diagnosis of hypocitraturia is usually
fixed as less than 320 mg per day. However, hypocitraturia may be severe (citrate excretion of less than
100 mg per day) or mild-moderate (from 100 to 320 mg), but low excretion (less than 640 mg per day)
could also be a significant sign and should be monitored [18]. In general, elevated citrate excretion
may be considered a non-pathological condition which reflects the restoration of the acid-base balance
and occurs, for instance, after chronic alkali intake [22]. Low citrate excretion is a relatively common
finding, and even though the majority of patients have idiopathic hypocitraturia, there are several
medical and physiological conditions associated with this abnormality. All the conditions listed in
Table 1 may be potentially associated with skeletal disorders or, more broadly, with bone metabolism
alterations, even when there are no obvious symptoms.
Table 1. Causes of low citrate excretion.
Cause Annotation
Acid-base status [16,23]
• Acidosis increases citrate utilization by the mitochondria in the
tricarboxylic acid cycle (TCA cycle), thus decreasing intra- and
extracellular availability. As a consequence, citrate reabsorption is
enhanced and urine excretion is reduced. On the contrary, alkalosis
increases citrate elimination.
Hypokalemia [16,23] • Low potassium levels cause intracellular acidosis (see above).
Diet [24,25]
• Low intake of high-citrate content food (fruit/vegetables).
• A diet rich in animal proteins contains sulfate and phosphate
moieties which are not metabolised and are excreted as acids which
decrease urinary pH and citrate excretion.
• High sodium intake, ketosis-promoting diet, and starvation.
Distal renal tubular acidosis
(dRTA) [26]
• Complete form (hyperchloremic metabolic acidosis, hypokalemia,
elevated urine pH).
• Incomplete form (normal serum electrolytes, inability to acidify
urine following an ammonium chloride load).
Chronic diarrheal syndrome
[16,23]
• The fluid loss and intestinal alkali wasting alter the acid-base status,
with low urinary pH and citrate retention.
Medications [16,23,27,28]
• Thiazide diuretics induce hypokalemia with resultant
intracellular acidosis.
• Acetazolamide (carbonic anhydrase inhibitor) produces changes in
urine composition which are similar to those found in dRTA.
• Angiotensin-converting enzyme inhibitors cause a reduction in
urinary citrate by increasing the adenosine triphosphate (ATP)
citrate lyase activity.
• Topiramate (carbonic anhydrase inhibitor) exerts a dose-dependent
effect on the renal excretion of citrate.
Strenuous physical exercise [23] • It causes lactic acidosis, producing hypocitraturia.
Hyperuricosuria [23]
• With normouricemia, generally caused by dietary excess of purines
(animal proteins).
• With hyperuricemia (gouty diathesis), the urinary pH is typically
low, with increased citrate reabsorption.
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Table 1. Cont.
Cause Annotation
Active urinary tract infection [23]
• Bacteria which degrade citrate lower the urinary
citrate concentration.
Chronic kidney disease (CKD) [29]
• The decrease in the glomerular filtration rate causes a stepwise
reduction in the amount of filtered citrate. Overt hypocitraturia is
usually observed in advanced stages of CKD.
Primary hyperaldosteronism [30]
• Hypocitraturia (and hypercalciuria) occurs via Na-dependent
volume expansion and chronic hypokalemia.
Menopause [31–34]
• Estrogen deficiency induces metabolic alteration related to the
lowering of estrogen-induced signaling onto the mitochondria
which promotes glycolysis and glycolytic-coupled TCA cycle
function. Hormone replacement therapy restores the citrate level
which is decreased in postmenopausal women.
Genetic defects [16]
• All inheritable diseases, gene defects, and polymorphisms
associated with the above mentioned conditions (additional details
in Table 2).
Modulation of citrate excretion in the kidney is influenced by multiple factors, but pH regulation,
particularly in the proximal tubule, has the strongest impact, and even a small decrease in tubular
pH significantly increases tubular reabsorption [16]. Therefore, in response to the elevated acid
load occurring in metabolic acidosis, there is a notable increase in citrate recovery with subsequent
hypocitraturia; urinary citrate excretion may be used as a laboratory parameter for monitoring the
diet- and metabolism-dependent systemic acid-base status, even in subjects without overt metabolic
acidosis [29,35,36].
The detrimental effect of acid-base imbalance on bone metabolism has been proven without
a doubt [36,37], thus suggesting that citraturia could be a noninvasive and indirect view of bone
health status. Actually, the relationship among urinary citrate excretion, bone quality parameters,
and circulating levels of bone turnover markers has been demonstrated [34,36], even if its clinical
usefulness is still controversial [37].
3. Citrate and Bone Tissue
In 1941 Dickens stated that approximately 90% of the total citrate found in the body of
“osteovertebrates” resides in mineralised tissues, but the most valuable insight was that, due to
its high binding affinity to calcium stored in the hard tissue, citrate could play a pivotal role in
regulating metabolic functions and in maintaining the structural integrity of bone [6]. Moreover,
Dickens postulated that the presence of citrate in bone is crucial for preventing calcium precipitation,
either when bone tissue is resorbed in response to lowered serum calcium or when the biomineralisation
process starts. Over time, data in the literature regarding the relationship between citrate and bone
physiology have been increasing exponentially (Figure 1), but the role of citrate in driving the structural
and functional properties of healthy bone in humans has only been partially elucidated. Early studies
were mainly aimed at searching for the origin and the role of calciotropic hormones (calcitonin,
parathyroid hormone (PTH), and vitamin D) in the regulation of its metabolism. However, these issues
have remained largely unresolved and/or highly speculative, due to the absence of necessary research
methodology and technology. Nowadays, there is adequate knowledge regarding the role of bone cells
in producing citrate, how citrate enters the crystalline structure of bone, and how it controls the size
and morphology of apatite nanocrystals.
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3.1. Citrate and Mineral Structure
Citrate is abundant in bone, representing 1–5 weight percent (wt%) of the organic components
with a density of approximately 1 molecule per 2 nm2, which implies that more than 15% of the
apatite surface area available in bone is covered by citrate molecules [38]. Before the introduction of
modern analytical techniques, the testing methods to evaluate bone tissue composition were entirely
limited to classic wet-chemical analyses. At that time, the evidence of a higher amount of the citrate
metabolic activity in bone as compared to other tissues, such as kidney or liver, was a significant
breakthrough. These findings allowed hypothesising that bone tissue was endowed with the special
capacity of producing and storing a high concentration of citric acid, and suggested the role of citrate in
regulating the mineralisation process [39]. On the one hand, citrate may influence the amount of mineral
deposition by complexing calcium-phosphate (CaP) and favouring its precipitation; on the other hand,
if citrate exceeds the amount incorporated in the bone matrix, it could even reverse the mineralisation
phase, thus functioning as a solubilising agent which recalls calcium ions. Hu et al. (2010) have proven
that citrate is not a dissolved solubilising agent but is firmly bound to apatite as an integral part of the
nanocrystal structure. This could be explained by the fact that the elevated amount of citrate in the
organic fraction (5.5 wt%) provides more COO- groups than all the noncollagenous proteins in bone,
and therefore, the chances of the binding between citrate and calcium of apatite are proportionally
increased [40]. Simultaneously, Xie and Nancollas (2010) proposed a three-phase model to explain
how citrate may influence the size, longitudinal growth and thickness of apatite nanocrystals [38].
The biomineralisation process initiates with the formation of the amorphous CaP phase starting from
an oversaturated CaP solution [41] (Figure 3A). At the early stage, few citrate molecules can bind
with the surface of small-size amorphous CaP clusters, but even so, they are sufficient to slow down
particle aggregation (Figure 3B). In the next phase, the noncollagenous proteins released from bone
cells promote the amorphous CaP cluster clumping, and apatite nucleation starts within these larger
amorphous aggregates. Moreover, the presence of collagen fibrils promotes the self-assembly of the
small amorphous CaP clusters and guides their direction on the collagen surface [42] (Figure 3C). At the
final stage, the surface of mature apatite nanocrystals is fully covered by citrate, so that the increase
in thickness is inhibited whilst the growth may continue in a longitudinal direction, thus explaining
the plate-like morphology which apatite crystals exhibit in bone [38]. The final apatite structure has a
unique geometry since it does not exceed 30–50 nm in length and maintains 2–6 nm thickness [43].
By using a combination of solid-state Nuclear Magnetic Resonance spectroscopy, powder X-ray
diffraction, and the principles of electronic structure calculations, Davies et al. (2014) postulated that
citrate anions could be incorporated in a hydrated layer of the CaP structure. This binding configuration
favours the growth of the mineral crystals in a plate-like morphology and explains their propensity
to form stacks [44,45] (Figure 3D). More recently, Delgado-Lopez et al. (2017) focused on the early
mineralisation phase, taking into account the interaction between citrate and collagen [46]. By means
of an in-depth characterisation based on X-ray scattering and imaging techniques, they found that
collagen and citrate work synergically to favour the platy morphology, since both contributed to
maintaining the transient amorphous phase. The amorphous CaP clusters are figured as spherulites or
globules which gradually occupy the gap zones of the aligned collagen fibrils [43].
The results of the above-mentioned studies confirmed that citrate is an integral part of the
apatite-collagen nanocomposite, and the degree of incorporation into bone mineral, as well as the
spatial orientation in the mineral structure, play a key role in maintaining the biomechanic properties
of bone, i.e., stability, strength, and resistance to fracture. In light of its structural role, citrate has been
used to explain the changes in the bone microarchitecture typical of some diseases [47]. In addition,
a series of citrate-based materials for orthopaedic applications have been developed to favour the
osteoinductive and osteoconductive properties of scaffolds for bone tissue engineering [48,49], as well
as to promote bone healing in other surgical procedures [50–52].
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of bone mineral platelets. In addition, citrate forms bridges between the mineral platelets which can 
explain the stacked arrangement which is relevant to the mechanical properties of bone. 
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Once the presence of high concentrations of citrate in bone tissue was proven and the role of 
citrate in the mineralisation process clarified, the main goal of research in this field was to understand 
what the source of citrate in bone tissue was. Costello et al. (2012) demonstrated that murine 
osteoblasts were able to secrete citrate [53], thus laying the groundwork for additional studies which 
elucidated the metabolic process. Basically, the mechanisms were similar to those demonstrated in 
the prostatic cell, which is the other highly specialised cell capable of releasing high levels of citrate 
into the extracellular fluid. The elevated level of citrate production is due to the low activity of 
mitochondrial aconitase. This enzyme activity is suppressed by the zinc (Zn2+) that is accumulated by 
cells through the solute carrier 39A (SLC39A1), also known as “zinc importer protein 1” (ZIP1) [54–
56]. 
Additional studies have confirmed that human osteoblasts were citrate-producing cells, that 
ZIP1 expression and intracellular zinc increased during the differentiation of the osteogenic 
precursors into bone-forming cells, that ZIP1 knockdown prevented the intracellular accumulation 
of citrate [5], and that ZIP1 expression was promoted by bone morphogenetic protein 2 during the 
mineralisation process [57]. In addition, the upregulation of the mitochondrial solute carrier 25A 
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Figure 3. Citrate in the formation of the mineral matrix. The figure combines the theories proposed
by different authors regarding the role of citrate in the mineralisation process [38,40,43–45]. (A) The
amorphous calcium-phosphate (CaP) phase originates from an oversaturated CaP solution, and the
mineralisation process starts when the organic phase (citrate, collagen fibrils, and oncollagenous
proteins) is available in the bone microenvironment. (B) At the early stage, few citrate molecules bind
wit the amorphous CaP and the particle aggregation is slowe down. (C) In the next phase, the
oncollagenous proteins released from ll favour CaP ag regation and ap tite nucleation while
th collagen promotes the self-assembly of CaP and gui es the aggregate deposition on the collagen
surface. (D) When the surface is fully covered by citrate, the hickness increase is inhibited (2–6 nm),
while longitudi al growth c ntinues up to 30–50 nm, thus explaining the flat morphology of bone
mi ral platelets. In addition, c trate forms bridges between th mineral platelets which can explain
the stacked arrangement which is relevant to the mechani al properties of bone.
3.2. Citrate and Bone Cells
Once the presence of high concentrations of citrate in bone tissue was proven and the role of citrate
in the mineralisation process clarified, the main goal of research in this field was to understand what
the source of citrate in bone tissue was. Costello et al. (2012) demonstrated that murine osteoblasts
were able to secrete citrate [53], thus laying the groundwork for additional studies which elucidated the
metabolic process. Basically, the mechanisms were similar to those demonstrated in the prostatic cell,
which is the other highly specialised cell capable of releasing high levels of citrate into the extracellular
fluid. The elevated level of citrate production is due to the low activity of mitochondrial aconitase.
This enzyme activity is suppressed by the zinc (Zn2+) that is accumulated by cells through the solute
carrier 39A (SLC39A1), also known as “zinc importer protein 1” (ZIP1) [54–56].
Additional studies have confirmed that human osteoblasts were citrate-producing cells, that ZIP1
expression and intracellular zinc increased during the differentiation of the osteogenic precursors
into bone-forming cells, that ZIP1 knockdown prevented the intracellular accumulation of citrate [5],
and that ZIP1 expression was promoted by bone morphogenetic protein 2 during the mineralisation
process [57]. In addition, the upregulation of the mitochondrial solute carrier 25A (SLC25A1), the
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citrate transport protein (CTP), was essential for the release of citrate from the mitochondria [56].
In order to define the gene expression patterns underlying the differentiation of mesenchymal stem cells
(MSCs) into mature osteoblasts, a large-scale transcriptome analysis starting from the bone-marrow
MSCs maintained in osteogenic medium up to deposition of mineral nodules was carried out [58].
While the role of ZIP1 was already described [5,56,59], the microarray analysis showed that solute
carrier 13A (SLC39A13), or ZIP13, was upregulated throughout osteogenic differentiation and was also
detectable during the mineralisation process [60].
As shown in Figure 4A–E, changes in the citrate metabolism occur during the whole process
of differentiation of the MSCs into mature osteoblasts. After the osteogenic commitment of resting
MSCs, a highly proliferative phase is expected, and the exportation of citrate into cytosol provides the
acetylCoA for the synthesis of the new lipids required for the assembly of the new plasma membranes
during cell duplication. Mitochondrial citrate seems to be the preferential source of acetylCoA,
since the alternative sources pose some limitations. In fact, extracellular citrate could be used for
lipogenesis; however, cellular uptake is subordinated to the expression of the specific transporter, i.e.,
“sodium-dependent citrate transporter” (NaCT; SLC13A5) [61]. AcetyilCoA could also be obtained
from plasma acetate passing through the cell membrane by means of the monocarboxylate transporter
(MCT/SLC16A). In order to use this source, the upregulation of acetylCoA synthetase is required, but
it is not highly expressed in mammalian cells [56]. Moreover, aconitase inhibition and the lack of
mitochondrial citrate affect the energy supply via the Krebs cycle, so that the bioenergetic demand for
proliferating/differentiating cells has to be satisfied by alternative sources. For instance, cytosol malate
may enter the mitochondrion by CTP in exchange for citrate and may be converted into oxalacetic acid,
which in turn may originate new citrate [56].
On the basis of recent studies, citrate released during the bone resorption phase could be considered
a matrix-derived signal which contributes to the overall process of bone remodelling within the “basic
multicellular unit” [62]. In this regard, Ma et al. have demonstrated that extracellular citrate played a
pivotal role regarding the osteogenic differentiation of MSCs [63]. This “metabonegenic” regulation
started with citrate uptake through the sodium-citrate transporter SLC13A5 followed by the activation
of energy-producing pathways leading to an elevated cell energy status, which in turn fueled the high
metabolic demands of MSCs differentiating into osteoblasts. In vitro experiments have shown that the
timing and dosage of the citrate supply were critical factors. In fact, the effects were dose-dependent and
more evident at the early stages of osteogenic differentiation, with higher proliferation and increased
expression of bone-related genes, i.e., alkaline phosphatase and alpha 1 chain of type I collagen [63].
Identical effects have also been observed in a microenvironment hostile to bone cells, for instance
using culture conditions which simulated low-grade acidosis [64]. In fact, citrate supplementation
opposed the detrimental effects resulting from extracellular acidosis, which inhibited the synthesis of
collagen and non-collagen proteins, the activity of alkaline phosphatase, and the formation of mineral
nodules [65].
Taken together, studies regarding the role of citrate in the nanocrystal structure and those showing
that osteoblasts were the specialised citrate-producing cells in bone have led to a new concept of bone
formation related to “citration”. Briefly, Costello et al. (2012) stated that . . . .”when considering the
mineralisation role of osteoblasts in bone formation, it now becomes evident that ’citration’ must be
included in the process. Mineralisation without ‘citration‘ will not result in the formation of normal
bone, i.e., bone that exhibits its important properties, such as stability, strength, and resistance to
fracture” [53].
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Figure 4. Citrate metabolism, osteoblast differentiation, and mineralisation process. The figure
combines the concept of “osteoblast citration” with the main steps of the differentiation of mesenchymal
stem cells (MSCs) into bone-forming cells (osteoblasts) [5,53,56]. (A) Resting MSCs are quiescent,
nonproliferating cells which exhibit the typical mitochondrial metabolism with the oxidation of citrate
via the Krebs cycle. (B) In the presence of proper stimuli, the undifferentiated MSCs are committed
to osteogenic differentiation and, at the early phase, high proliferation is required. To accomplish
this goal, the following events are necessary: (1) the upregulation of ZIP1 which promotes the zinc
intake, (2) the accumulation of mitochondrial citrate due to the zinc-dependent inhibition of the
mitochondrial aconitase, (3) the exportation of citrate into cytosol by means of the “citrate transport
protein” (CTP/SLC25A1), (4) the use of cytosol citrate for the lipogenesis process which is essential
for cell duplication. (C,D) The citrate exportation from cytosol to extracellular fluid starts during cell
differentiation, and it is simultaneous for the synthesis and the release of amorphous CaP, collagen,
and noncollagenous proteins. (E) The “osteoblast citration” is completed when the mineralised matrix
is assembled. The role of citrate in growing the apatite nanocrystals and driving the mineralisation
process is explained in Figure 3.
4. Citrate Pathophysiology and Bone Diseases
The role of citrate in mineralised tissues poses several questions regarding the consequences of a
low bioavailability at the systemic level. For the most part, published data linking citrate alteration
with bone metabolism refer to renal diseases, acid-base imbalance or also physiological conditions such
as menopause, but there are also inheritable genetic defects which affect the TCA cycle in mitochondria
or the citrate transport. In the following paragraphs, the medical conditions in which the association
between citrate and bone health status has been implied are discussed.
4.1. Bone Health Status and Alterations of Citrate Homeostasis in Kidney Diseases
With the progressive aging of the population, epidemiological studies have shown a higher
rate of elderly-related illnesses, including the impairment f bone quality leading to osteoporosis
and creased rena function with chronic kidney disease (CKD), which in turn may influence bone
h alth status [66–68]. The de rease in re al function may be mild, moderate or sever on the basis
of estimated-glomerular filtration rate (GFR) equations and is associated with the simult neous
impairment of mine al homeostasis, including serum and tissue concentrations of phosphorus and
calciu , circulating levels of calciotropic hormones (PTH, 25-hydroxyvitamin D, 1,25-di ydroxyvitamin
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D), fibroblast growth factor-23, and growth hormone. The modifications of mineral homeostasis may
promote a loss of bone mass and an increase in bone fragility [69]. As observed by Malmgren et al.
(2015), approximately 95% of women over 75 years of age showed a mild-moderate decrease in renal
function (CKD stages 2–3) which may have had a harmful effect on bone health [70]. In a 10-year
longitudinal study, the authors evaluated the long-term influence of impaired renal function on bone
mineral density (BMD) [71]. They analysed 1044 Caucasian women from the “Osteoporosis Prospective
Risk Assessment” (OPRA) cohort and found that renal function was positively correlated with femoral
neck BMD in elderly women, although the association attenuated as aging progressed. Women with
poor renal function had a higher annual rate of bone loss over 5 years compared to those with normal
function, and markers of mineral homeostasis were more frequently altered.
High-throughput “omics” approaches, including metabolomics, have been proposed to identify
new biomarkers which could help the management of CKD patients, and TCA cycle-metabolites are
emerging as potential candidates [72]. A significantly reduced urinary excretion of citrate (–68%) has
been observed in non-diabetic patients with CKD as compared to subjects with normal renal function.
The renal expression of genes regulating the TCA cycle was decreased in subjects who had impaired
renal function, thus suggesting that mitochondrial dysfunction could be involved in the pathogenesis
of CKD [73]. Moreover, GFR positively correlated with citrate excretion, and kidney stone formers
with CKD had significantly lower urinary citrate excretion than subjects with kidney stone disease and
normal renal function [74].
To the authors’ knowledge, the link between CKD, urinary citrate and bone health status has still
not been elucidated but, taking into account the information emerging from the previous paragraphs,
it is reasonable to assume that the link exists. Some indications have derived from the data regarding
kidney stone disease, which is the paradigmatic expression of a relationship between citrate alterations,
BMD decrease and fracture risk that has been investigated since the 1970s [75]. In fact, several studies
have shown that osteoporotic fractures occurred more frequently in patients with kidney stones than
in the general population [76–79].
The connection between kidney stones and bone metabolism is related to several factors. Briefly,
kidney stones form when urine becomes supersaturated with respect to its specific components. Since
80% of kidney stones are composed of calcium-oxalate (CaOx) or CaP, the regulation of calcium
excretion plays a pivotal role in the etiopathogenesis of nephrolithiasis [80]. As urinary citrate is
able to bind calcium and prevent the growth and agglomeration of CaOx and CaP crystals, the close
relationship between low citrate excretion and kidney stone formation has been fully established [11].
The incidence of hypocitraturia varies from 20% to 60% in people who have a propensity to form stones,
either as a single abnormality or in conjunction with other metabolic disorders [16]. Hypercalciuria
may occur either when filtered calcium is abnormally increased or when its reabsorption is abnormally
decreased. The former may be associated with enhanced bone resorption which raises calcium
bioavailability at the systemic level, while the latter may be the consequence of decreased renal
function as occurs in CKD. Theoretically, reduced GFR in CKD should lead to decreased urinary
calcium concentration, but the consequences of defective tubular reabsorption are more relevant and
are responsible for the supersaturation of calcium salts. In addition, in the distal nephron, calcium
reabsorption is a PTH-dependent process, PTH being the hormone capable of stimulating the resorption
of the bone matrix in response to low, systemic calcium availability [81]. Therefore, as the decrease
in the renal function progresses, PTH levels and bone loss gradually increase, thus explaining why
kidney stones are a significant predictor of osteoporotic fracture in patients with CKD [82]. Moreover,
when nephrolithiasis occurs, patients are frequently advised to reduce calcium intake, thus favouring a
negative calcium balance which is an additional risk factor promoting a decrease in BMD [11].
Recent findings have demonstrated that lithogenic risk factors, including hypocitraturia, are also
detectable in patients without kidney stones who exhibit osteoporosis or osteopenia, thus leading to
the hypothesis that the evaluation of lithogenic risk could have significant implications for monitoring
bone health status [34,83].
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4.2. Postmenopausal Osteopenia and “Net Citrate Loss”
Estrogen deficiency and aging are the main factors responsible for the depletion of bone mass [84],
but they are also associated with changes in urine composition which are similar to those of subjects
having an increased risk of kidney stones [11]. The circulating citrate levels and the citrate content
in bone are markedly reduced in animals with age-related or ovariectomy-induced bone loss [85].
A low citrate excretion, less severe than true hypocitraturia fixed at less than 320 mg per day, has been
described in postmenopausal women [11,33] and in subjects with a low bone mass [34,83]. Nurses’
Health Study II considered an ongoing cohort of 108,639 participants from whom information on
menopause and kidney stones was obtained. In general, postmenopausal status was associated with
lower BMD and a higher incidence of kidney stones in this cohort. Moreover, small but significant
differences in urine composition were found in 658 participants who had pre- and postmenopausal
24-h urine analyses, including a lower citrate excretion [86].
The postmenopausal decline in estrogen concentration influences the activation rate of basic
multicellular units composed of bone-resorbing osteoclasts and bone-forming osteoblasts. However,
according to Drake et al., resorption increased by 90% while formation increased by only 45% [87] and
the final result was a “net bone loss”. This imbalanced bone remodelling depends on the effects that
the lack of estrogen has on bone cells. On the one hand, the activity of the receptor activator of the
nuclear factor-κ B ligand (RANKL) is promoted, a key factor in osteoclast differentiation; on the other
hand, the osteogenic precursors are destined to differentiate into adipocytes, and the survival of mature
osteoblasts is suppressed [88]. The result is the reduction of mature osteoblasts, and since they are the
cells capable of synthesising citrate [5], the consequence is lower citrate production which impairs
the quality and the stability of the bone microarchitecture [38,40]. Moreover, osteoclast differentiation
and bone resorption are energy-demanding processes, and the citrate which is synthesised cannot be
accumulated because it is essentially utilised through the citric acid cycle [89,90]. Similarly, the MSC
differentiation towards adipocytes requires more citrate as a source of cytosolic acetylCoA for lipid
biosynthesis [85]. In conclusion, according to Granchi et al., estrogen deficiency leads to a “net citrate
loss” which could explain the diminished citrate excretion observed in postmenopausal women [91].
4.3. Genetic Variations Influencing Citrate Homeostasis and Skeletal Development
The “Online Mendelian Inheritance in Man®” database (OMIM®) is a comprehensive repository
of information on the relationship between genetic variation and phenotypic expression [92].
The annotations connecting citrate homeostasis with skeletal defects are listed in Table 2, and many of
these concern Slc proteins, which are a family of solute transporters through the membranes.
Mutations of the Cl2/HCO3·2 exchanger AE1, encoded by SLC4A1 which is expressed in red blood
cells and in type A intercalated cells of the renal collecting tubule, may be responsible for distal renal
tubular acidosis (dRTA), with or without haemolytic anemia. The corresponding phenotype displays
defective urine acidification, nephrocalcinosis, nephrolithiasis, hypercalciuria, and hypocitraturia [93].
The clinical phenotype in patients with inherited dRTA is characterised by stunted growth with
bone abnormalities in children, as well as nephrocalcinosis and nephrolithiasis which develop as the
consequence of hypercalciuria, hypocitraturia, and relatively alkaline urine.
The same cytogenetic location of SLC4A1 (17q21.31) is involved in Glycogen storage disease Ia
which is caused by a deficiency in glucose-6-phosphatase activity that catalyses the synthesis of glucose
from glucose-6-phosphate. This enzymopathy results in a failure to maintain normal glucose control
with glycogen accumulation in the liver, kidney, and intestine. Low citrate excretion and hypercalciuria
have been described by Weinstein et al. (2001), and the combination of these metabolic alterations
correlated with the onset of nephrocalcinosis and nephrolithiasis [94]. Furthermore, there is increasing
evidence that poor metabolic control, including chronic acidosis (lactic), low muscle mass and delayed
puberty, may negatively affect BMD in half of the patients [95].
NaCT is the sodium-coupled tricarboxylate transporter predominantly expressed in the liver,
at several-fold lower levels in the testis and the brain, and at weak levels in the kidney and the heart.
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The association between the mutations of the SLC13a5 gene on chromosome 17p13 and early infantile
epileptic encephalopathy-25 with amelogenesis imperfecta has been clearly recognised [96]. More
recently, Irizarry et al. have shown that SLC13a5 deficiency led to decreased BMD and impaired bone
formation in homozygote (Slc13a5-/-) and heterozygote (Slc13a5+/-) mice [97]. As shown by Diaz et al.
(2017), the epigenetic modulation of SLC13a5 gene may also influence skeletal development, since
DNA hypermethylation and low gene expression have been found in the placenta and cord blood of
infants born small-for-gestational-age and correlated with low height and weight at birth, low BMD,
and low mineral content [98].
Bartter syndrome refers to a group of autosomal recessive disorders characterised by impaired
salt reabsorption in the thick ascending limb of the loop of Henle with pronounced salt wasting,
e.g., potassium and calcium, and hypokalemic metabolic alkalosis [99]. The antenatal variant
or Bartter syndrome type I is caused by a homozygous or compound heterozygous mutation in
the sodium-potassium-chloride cotransporter-2 gene [100]. The affected infants develop marked
hypercalciuria and, as a secondary consequence, nephrocalcinosis and osteopenia [101]. To the best of
the authors’ knowledge, low citrate excretion in patients affected by Bartter syndrome has not been
described, but citrate potassium administration is able to correct biochemical alterations [102,103].
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is an autosomal-recessive
renal tubular disorder caused by mutations in claudin-16 and claudin-19, which are members of the
transmembrane family proteins regulating calcium and magnesium reabsorption in the kidney [104].
Thorleifsson et al. have also identified claudin-14 as a major risk gene of hypercalciuric nephrolithiasis
associated with a decrease in BMD [105]. Patients can develop hypomagnesaemia, hypercalciuria,
and nephrocalcinosis, and their clinical course is often complicated by the progressive loss of kidney
function. Other biochemical anomalies consist of elevated serum PTH levels before the onset of CKD,
incomplete distal tubular acidosis, hyperuricemia and hypocitraturia [106]. Additional symptoms may
be recurrent urinary tract infections, nephrolithiasis, polyuria, polydipsia and/or failure to thrive [106].
Amelogenesis imperfecta has also been described in some patients [107].
The human gene SLC13A2 encodes the sodium-dicarboxylate cotransporter (NaDC1) which is
highly expressed in the brush-border membranes of the renal proximal tubule and intestinal cells, and
reabsorbs Krebs cycle intermediates, i.e., succinate and citrate [108]. Although to date no distinctive
phenotype has been linked with SLC13A2 variation in the OMIM database, Okamoto et al. (2006) have
hypothesised that NaDC1 alterations could play a role in the development of kidney stones by affecting
the citrate concentration in the urine [109]. The functional properties and protein expression of eight
coding region variants of NaDC1 have recently been characterised; the majority of them appeared to
decrease transport activity and were predicted to result in decreased citrate absorption in the intestine
and kidney [110]. Even if not investigated, it is reasonable to assume that effects on bone mass may
occur since these conditions influence citrate metabolism and predispose to renal stone formation
as well.
The mitochondrial CTP, coded by the SLC25A1 gene located on chromosome 22q11.21, is embedded
in the inner membrane and determines the efflux of tricarboxylic citrate from the mitochondria to
cytosol in exchange for dicarboxylic malate [111]. The high citrate concentration into cytoplasm
modulates the lipid synthesis and affects glycolysis by inhibiting phosphofructokinase-1 [112]. Genetic
variations of SLC25A1 mainly lead to inheritable diseases featured by alterations of the central nervous
system (combined D-2- and L-2-hydroxyglutaric aciduria; OMIM ID: 615182) and skeletal muscle
(congenital myasthenic syndrome-23; OMIM ID: 618197) while the presence of bone defects is less
relevant. However, SLC25A1 impairment also occurs in the 22q11.2 deletion syndrome which is
characterised by congenital absence of the thymus and parathyroid glands as well as cardiac, renal and
eye anomalies, developmental delay, and also skeletal defects. As additional evidence of a relationship
between citrate transport and bone pathophysiology, it has been shown that SLC25A1 knockout in
mice causes a notable decrease in the number of osteoblasts and the amount of osteoid [113].
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As mentioned above, zinc plays a crucial role in regulating the extracellular bioavailability of
citrate in the formation of new mineralised matrix and, therefore, gene defects involving a zinc
transporter may be involved in alterations of the citrate metabolism and bone diseases. Of these,
the solute carrier 39A family (SLC39A or ZIP) controls the influx of zinc into the cytoplasm [56].
In a previous study, the authors found that SLC39A13 (ZIP13) is upregulated throughout osteogenic
differentiation, and no changes were recorded during the mineralisation process [58]. SLC39A13
gene defects have been associated with low bone mass in knockout mice [56] and spondylodysplastic
Ehlers-Danlos syndrome, type 3 (Phenotype MIM number 612350).
Table 2. Genes involved in the regulation of citrate homeostasis with a genotype/phenotype relationship
regarding skeletal development and/or bone metabolism (retrieved from the OMIM®database, last
access 25 May 2019).
Gene/Locus Name Gene/Locus CytogeneticLocation
MIM Number:
Phenotype Inheritance
Solute carrier family 4, anion
exchanger, member 1 (erythrocyte
membrane protein band 3, Diego
blood group)
SLC4A1, AE1,
EPB3, SPH4, SAO,
CHC
17q21.31 179800: Distal renaltubular acidosis
Autosomal
dominant
Solute carrier family 4, anion
exchanger, member 1 (erythrocyte
membrane protein band 3, Diego
blood group)
SLC4A1, AE1,
EPB3, SPH4, SAO,
CHC
17q21.31 611590: Distal renaltubular acidosis
Autosomal
recessive
Glucose-6-phosphatase, catalytic G6PC, G6PT 17q21.31 232200: Glycogenstorage disease Ia
Autosomal
recessive
Solute carrier family 13
(sodium-dependent citrate
transporter), member 5
SLC13A5, NACT,
INDY 17p13.1
615905: Early
infantile, epileptic
encephalopathy, 25
Autosomal
recessive
Solute carrier family 12
(sodium/potassium/chloride
transporters), member 1
SLC12A1, NKCC2 15q21.1 60167: Barttersyndrome, type 1
Autosomal
recessive
Claudin 16 (paracellin 1) CLDN16, PCLN1,HOMG3 3q28
248250: Renal
hypomagnesemia 3
Autosomal
recessive
5. Medical Management of Patients with Metabolic Bone Diseases Associated with
Citrate Alterations
5.1. Clinical Work-Up
At present, the guidelines dealing with the clinical management of metabolic bone diseases do
not highlight the role of citrate in maintaining bone integrity. Nevertheless, based on research findings,
the causes of hypocitraturia should be considered in carrying out a complete evaluation of patients
who present BMD alterations; vice versa, the accurate monitoring of BMD is advisable in subjects who
have reduced urinary citrate excretion.
Regarding laboratory investigations, citrate homeostasis should be evaluated together with all
factors which influence mineral metabolism. Although citrate excretion must be measured over a
24-h period and referred to the 24 h-urine volume, the detection of citrate levels in fasting-morning
urine (expressed as creatinine ratios) may be an addional element to complete the metabolic profile.
Urine pH can be a valid and simple indicator of acid-base balance. Laboratory testings for evaluation
of mineral metabolism have to be carried out on plasma and urine by considering renal function,
calcium-phosphorus balance, other electrolytes (in particular, potassium and magnesium), and
calciotropic hormones. In addition, bone turnover markers (BTMs), including bone-resorption and
bone formation indicators, are considered a useful and inexpensive tool for evaluating turnover rate
(high or low) and response to any treatment [114].
Quantitative assessment of BMD is mandatory for evaluating bone health status and for calculating
fracture risk [115]. Dual-energy X-ray absorptiometry (DXA), the T score (the number of standard
deviations above or below the mean for a healthy 30-year-old adult of the same sex and ethnicity), or the
Z-score (the number of standard deviations above or below the mean for the patients of the same age,
sex and ethnicity) are employed for measuring areal density (g·cm−2) at any skeletal site. The assesment
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of bone quality may be additionally explored by evaluating the trabecular bone score which reflects
bone microarchitecture [116]. “High-resolution peripheral quantitative computed-tomography” allows
an accurate assessment of bone strength; however, due to its elevated cost, the diffusion of this
technology is still limited.
Even though noninvasive techniques are preferred, bone biopsy remains a valid tool for assessing
the tissue quality in metabolic bone diseases, and it is the gold standard for estimating bone impairment
in kidney disease and for guiding the clinician in deciding proper treatment [117]. In fact, according to
the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the term renal osteodystrophy
may be used exclusively to define the histological alterations in bone morphology associated with
CKD, which can be additionally assessed using histomorphometry. Instead, without histological
confirmation, the clinical syndrome which develops as a systemic disorder of the mineral and the bone
metabolisms is generally called “CKD-Mineral and Bone Disorder” [69,118]. However, bone biopsies in
a routine work-up present some drawbacks, which are foremost the availability limited to specialised
centres, discomfort for the patients, and the length of time required to process and analyse bone tissue.
Whenever instrumental and laboratory investigations show a significant bone loss, pharmacological
treatment has to be planned according to the indications of the current guidelines, eventually adding
specific drugs in case of secondary osteoporosis. Moreover, all recommendations related to lifestyle
and dietary modifications should be explained to the patient [115]. In the presence of low urine citrate
excretion, citrate-based supplements could be recommended to prevent progressive damage to bone
and a progressive reduction in BMD.
5.2. Dietary Modification
Since hypocitraturia may depend on food habits (Table 1), dietary modifications should be
considered as a first level intervention for the medical management of citrate deficiencies. Diet is aimed
at correcting the excessive acid load and, as a consequence, the negative effects that acidosis has on
bone metabolism [119]. The acid-ash hypothesis emphasises the role of the skeleton in maintaining the
acid-base balance since the hydroxyapatite of the mineral matrix is a reservoir of alkali groups which
may be released to neutralise proton excess [120]. Acute and chronic acid loading show distinct effects,
with acute acidity first eroding the bone surface to release sodium, potassium and bicarbonate into
the circulation, while chronic acidity leads to the release of calcium and phosphate [121]. Moreover,
acidosis directly influences the activity of bone cells within the bone remodelling unit by promoting
osteoclast-mediated resorption and inhibiting bone formation by osteoblasts [65]. Hypocitraturia is a
response to the elevated acid load occurring in metabolic acidosis, since there is a notable increase in
citrate reabsorption in the renal proximal tubule when the tubular pH decreases [16]. In this regard, there
is consensus in considering citraturia as a biomarker for monitoring diet and the metabolism-dependent
systemic acid-base status, even in subjects without overt metabolic acidosis [33–35].
Under physiological conditions, the acid-base balance is strictly controlled by net endogenous
acid production related to acid and alkali dietary intake, and incomplete metabolism of organic acids.
By using proper methods, such as “net endogenous acid production” (NEAP) [122] and “potential
renal acid load” (PRAL) [123], it is possible to determine the production of acids and characterise foods
according to their ability to release acids and bases into the bloodstream. The prolonged and excessive
consumption of acid precursor foods leads to chronic low-grade metabolic acidosis which reduces
the excretion of citrate and predisposes to diseases [124], including alteration of bone health status,
especially in older subjects with diminished renal function [125]. Some authors have discarded the
acid-ash hypothesis, claiming that the increase in the diet acid load did not promote skeletal bone
mineral loss or osteoporosis [126], and the main role in regulating acid-base homeostasis should be
attributed to the kidney [127]. However, the above studies did not consider the role played by citrate
in preserving the mineralised matrix and it would be interesting to know whether the relationship
between acid dietary intake and alterations in the bone metabolism varied according to low or normal
urine citrate excretion. As supporting evidence for the link between citrate and bone health, previous
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studies have demonstrated a positive correlation between citrate excretion and radius densitometric
values in pre- and postmenopause, as well as a significant relationship between citraturia and the
prevalence of vertebral fracture in postmenopausal women [11].
The general dietary approach to counteract elevated acid load is to limit the intake of foods with a
high acidifying potential, i.e., meat (beef, pork, poultry), fish and seafood, eggs, beans and oilseeds,
in favour of foods which contribute the most to the release of bases, i.e., fruits and vegetables [128].
However, dietary modifications cannot disregard the medical history of the patients, and the best
nutritional approach should be evaluated on a case-by-case basis. For instance, in the elderly, inadequate
protein intake could be a greater problem for bone health than protein excess [129], and the intake of
high amounts of fruits and vegetables could be contraindicated in patients with CKD due to their high
potassium content [130].
The intake of foods with a high citrate content may be a valid approach to compensate for the
high demand due to acidosis or other causes of hypocitraturia [24,124]. The daily citrate intake is
approximately 4 grams, and almost all citrate introduced by exogenous sources is absorbed into the
gastrointestinal tract, arrives in the liver and is metabolised to bicarbonate [11].
Prezioso et al. (2015) examined the relationship between a diet rich in vegetables and urinary
citrate excretion [24]. Fruits and vegetables (except for those with high oxalate content) favour citrate
excretion; consequently, they decrease urinary saturation for CaOx and CaP, thus having a protective
effect on the formation of kidney stones [24]. In general, fruit intake is lower in hypocitraturic than in
normocitraturic subjects [131].
In order to provide dietary recommendations aimed at correcting hypocitraturia, Haleblian et al.
(2008) carried out an exhaustive analysis of citrate concentrations in citrus juices, noncitrus juices, and
commercially available beverages. The highest concentration was found in grapefruit juice (35% more
than in lemon juice), and a glass corresponded approximately to a 40 mEq tablet of potassium citrate.
In general, commercial beverages had lower amounts of citrate [7].
Several authors have studied the possible influence of the consumption of fruit juices (both citrus
and noncitrus) on urinary citrate excretion. Orange juice increased the excretion of urinary oxalate,
and therefore, its consumption could result in the biochemical modification of stone risk factors [132].
It should also be noted that grapefruit juice significantly increased urinary oxalate levels, but it was
not associated with an increased lithogenic risk probably due to the protective effect of the high citrate
content [133]. Regarding noncitrus juices, cranberry juice had a controversial effect on urine citrate (no
effect or an increase of 31%), but resulted in a significantly increased concentration of urinary calcium
and oxalate. In addition, diluted blackcurrant juice and melon had a positive effect in increasing
citraturia [24]. In a recent meta-analysis, Pachaly et al. aimed at systematically investigating the
effects of dietary measures on urinary citrate and nephrolithiasis [124]. They searched for randomised
controlled and crossover studies which evaluated urine citrate excretion after the intake of citrus-based
beverages, including fruit juices and soft drinks, calcium/magnesium rich mineral water, a high-fibre
diet, a low-animal-protein diet, and plant extracts. The authors identified thirteen studies involving
358 participants, the majority of whom were stone formers. Summarised estimates showed a significant
increase in citraturia levels only in subjects who consumed fruit juice and other beverages while the
other dietary modifications did not determine significant changes [7,8].
Clinical trials aimed at evaluating whether an increase in dietary citrate preserved the bone health
status are lacking. In a clinical trial, postmenopausal women were randomised into four groups, i.e.,
a diet (additional daily portion of 300 g of self-selected fruit and vegetables), two doses of potassium
citrate (12.5 and 55.5 mEq/day) and a placebo (control group). The participants were followed for two
years, and the effects on bone turnover were determined by measuring BTMs and BMD. The authors
concluded that neither potassium citrate nor fruit and vegetables influenced bone turnover or prevented
BMD loss over 2 years in healthy postmenopausal women (Table 3) [134].
In summary, natural sources of dietary citrate should be considered as a first option for preventing
kidney stone recurrence as an alternative to medical treatment [24]. From a theoretical point of view,
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published data have suggested that dietary modifications could also be effective in preserving bone
health. However, at present, there is insufficient evidence supporting the use of natural sources of
citrate as the sole treatment for preventing bone loss.
5.3. Citrate-Based Supplements
Nephrolithiasis was the first clinical condition in which oral citrate supplementation showed
therapeutic efficacy, particularly in lowering high stone recurrence rate which is more prevalent in
people with low urinary citrate levels [11]. The rationale for using citrate salts in kidney stone disease
was explained in previous paragraphs and was based on four main issues: (1) citrate salts are rapidly
absorbed through the intestine and equally rapidly filtered in the urine; (2) citrate forms calcium
citrate complexes, which in turn increase solubility and decrease the amount of free calcium in urine;
(3) citrate acts as an inhibitor of CaOx and CaP crystal growth and aggregation, and (4) in the intestine,
the complexation between calcium and citrate reduces enteric absorption of calcium, and therefore
renal excretion. A recent systematic review has demonstrated that citrate-based therapy reduced
recurrent calcium urinary stone formation compared to controls (placebo, usual care) [135]; however,
evidence was limited in children [136].
There have also been interventional clinical trials concerning the effect of citrate supplements
in preserving bone health status. As stated for dietary modifications, the rationale of the published
trials was based on the assumption that citrate-based supplements may be useful as alkalising agents
which neutralise the effects of an excessive acid load [16,65,119–121]. Other than diets rich in salt and
animal protein [128], several conditions may induce low-grade acidosis, and the majority of them
are age-related, such as menopause [33], subclinical inflammatory status [137], and decreased renal
function [68]. On the basis of this assumption, Lambert et al. (2015) carried out a meta-analysis
aimed at determining whether alkaline potassium salts, including potassium citrate and potassium
bicarbonate, had some effect on calcium metabolism and bone health [138]. The seven eligible
studies dealing with potassium citrate supplementation did not include subjects with nephrolithiasis
and/or other relevant comorbidities in order to avoid confounding factors potentially leading to
overestimation or underestimation of the intervention. Citrate salts significantly reduced calcium and
acid excretion similarly to potassium bicarbonate, but they seemed to be more effective in preventing
collagen resorption. However, insufficient data were available regarding changes in BMD, since it
was investigated in only two studies. The authors found major differences in terms of study design,
inclusion/exclusion criteria, doses, timing of supplement administration and outcome measures; this
heterogeneity represented a notable limitation for translation into a clinical setting.
In the current review, the interventional clinical trials which were primarily aimed at evaluating
the effect of citrate supplements on mineral metabolism and bone turnover were reviewed. Sixteen
eligible studies were identified which (1) recruited more than 10 subjects, (2) excluded nephrolithiasis
and other significant comorbidities and (3) reported the results related to bone health status, including
BMD and/or BTMs. Data regarding study design, population, intervention, follow-up, additional
supplementation or controlled dietary intake, as well as a summary of results and conclusions, are
shown in Table 3.
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Table 3. Interventional clinical trials based on the use of citrate supplements with primary or secondary outcomes related to bone health status.
Reference Study Design; Population
Intervention
(Dose/Day) (I)
Control (C)
Other
Supplements
(Dose/Day)
and/or
Controlled
Dietary Intake
Follow Up and
Outcomes
BTM Changes
(Intragroup)
Changes in BTM and BMD
Induced by Intervention
(Intergroup)
Conclusion
Dawson-Hughes,
1990 [141]
RCT, controlled vs placebo,
double-blind;
≥6 months postmenopausal
women (early, <5 years: n =
67; late, >5 years: n = 169);
age ≥ 65 years
I 1: Ca citrate malate
(500 mg Ca), n = 78
I 2: Ca carbonate (500
mg Ca), n = 78
C: Placebo (n = 80)
Controlled Ca
intake
Baseline, 18, 24, 36
months;
BTM (BAP) and BMD
I 1: 24 months ↓ BAP
I 2: 24 months ↓ BAP
C: 24 months ↓ BAP
BTM
I 1 vs. C: 36 months ↓ BAP,
related to the Ca intake
I 2 vs. C: 36 months ↓ BAP,
related to the Ca intake
BMD
I 1 vs. C: 12, 24 months ↑ only
in late postmenopause and Ca
intake ≤400 mg/day
I 2 vs C: ↓ in both groups
Adequate Ca intake is
essential in preventing
postmenopausal bone loss; Ca
citrate is more effective than
Ca carbonate.
Dawson-Hughes,
1997 [142]
RCT, controlled vs. placebo,
double-blind;
healthy subjects living in a
community (176 M/ 213 F);
age ≥ 65 years
I: Ca citrate malate (500
mg Ca) & Vit D3 (700
IU), n = 187
C: Placebo, n = 202
Controlled Ca
intake
Baseline, 6, 12, 18, 24,
30, 36 months;
BTM (OC, u-NTX) and
BMD
I: n.s
C: n.s.
BTM
I vs. C: 36 months ↓ OC
BMD
I vs. C: 36 months ↑
Ca and vitamin D
supplementation leads to a
moderate reduction in bone
loss and may substantially
reduce the risk of
nonvertebral fractures among
elderly subjects who live in
the community.
* Ruml, 1999
[143]
RCT, controlled vs. placebo;
postmenopausal women
(90% ≤5 years)
I: Ca citrate (800 mg Ca),
n = 25
C: Placebo, n = 31
Baseline, 12, 24
months
BTM (BAP, OC,
u-NTX, u- OH proline)
and BMD
I: all BTMs are ↓, at
unspecified time points
BMD
I: 24 months, stable
Ca citrate supplementation
averted bone loss and
stabilised bone density in
early postmenopausal
women.
Sellmeyer, 2002
[144]
RCT, controlled vs. placebo,
double-blind;
≥2 years postmenopausal
women; age I: 65 ± 8 years;
C: 63 ± 8 years
I: K citrate (90 mmol), n
= 26
C: Placebo, n = 26
Ca carbonate (500
mg); controlled
salt intake
Baseline, 1 months;
BTM (OC, u-NTX)
I: n.s.
C: 1 month ↓ OC, ↑
u-NTX
BTM
I vs. C: 1 month, ↓ u-NTX
K citrate prevents increased
bone resorption due to high
salt intake.
Dawson-Hughes,
2002 [145]
RCT, controlled vs. placebo,
double-blind;
healthy subjects (161 M/
181F); normal BMD; age ≥
65 years
I: Ca citrate malate (500
mg Ca), n = 158
C: Placebo, n = 184
Vitamin D3 (700
IU); controlled
protein intake
Baseline, 18, 36
months;
BTM (OC, u-NTX) and
BMD
I: 36 months ↓ u-NTX,
related to the protein
intake;
C: n.s.
BTM
I vs C: 36 months, ↓ u-NTX
BMD
I vs C: 36 month, ↑ related to
the protein intake
BMD may be improved by
increasing protein intake as
long as an adequate intake of
Ca and vitamin D is assumed.
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Table 3. Cont.
Reference Study Design; Population
Intervention
(Dose/Day) (I)
Control (C)
Other
Supplements
(Dose/Day)
and/or
Controlled
Dietary Intake
Follow Up and
Outcomes
BTM Changes
(Intragroup)
Changes in BTM and BMD
Induced by Intervention
(Intergroup)
Conclusion
Marangella, 2004
[146]
Controlled vs. untreated;
postmenopausal women; T
score: <−1.0; age: 43–72
years
I: K citrate 37-74 mEq
(≈1 mEq/kg), n = 30
C: No treatment, n = 24
Controlled Ca
intake
Baseline, 3 months
BTM (BAP, OC, u-OH
proline, u-DPD)
I: 3 months ↓ OC, u-OH
proline, u-DPD;
C: 3 months ↑ OC
not shown
K citrate decreases bone
resorption thereby contrasting
the potential adverse effects
caused by chronic acidemia.
The implication for the
prevention and treatment of
postmenopausal osteoporosis
has to be confirmed.
Kenny, 2004
[147]
RCT, crossover, open label,
2 phases; 3 months/phase
with a washout period of 2
weeks between phases;
postmenopausal women; T
score: <−1.0 and >−3.5; age:
73 ± 5 years
I 1: Ca citrate (1000 mg
Ca), n = 20;
I 2: Ca carbonate (1000
mg Ca), n = 20
Vitamin D3 (900
IU); controlled Ca
intake
Baseline, 1, 3 months
(each phase)
BTM (BAP, OC, NTX,
u-CTX, u-NTX,
u-DPD)
I 1: 3 months ↓ NTX,
u-CTX, u-NTX, u-DPD
I 2: n.s
Ca citrate inhibits bone
resorption more than Ca
carbonate.
Sakhae, 2005
[139]
RCT, crossover, placebo
controlled, double-blind, 4
phases; 2 weeks/phase with
a washout period of 2
weeks between phases;
postmenopausal women;
age: 48–76 years
I 1: K citrate (40 mEq), n
= 18
I 2: Ca citrate (800 mg),
n = 18
I 3: K citrate (40 mEq)
and Ca citrate (800 mg),
n = 18
C (1st phase): Placebo, n
= 18
Rigid diet with
fixed content of
protein, Ca, P, Na,
K and fluids
Baseline and at the
end of each phase;
BTM (BAP, CTX, OC,
u-NTX, u-OH proline)
I 1: n.s
I 2: ↓ CTX, u-OH proline
I 3: I: ↓ CTX, u-OH
proline, u NTX
I 3 vs I 1: ↓ u NTX
In postmenopausal women,
combined treatment with K
citrate and Ca citrate
decreases bone resorption by
providing an alkali load and
increasing absorbed Ca.
Jehle, 2006 [148]
RCT, controlled;
≥5 years postmenopausal
women; T score −1/−4; age:
≤70 years
I: K citrate (30 mEq), n =
82
C: KCl (30 mmol), n = 79
Ca carbonate (500
mg), Vitamin D3
(400 IU); free,
nonvegetarian diet
Baseline, 3, 6, 9, 12
months;
BTM (BAP, CTX, OC,
u-DPD, u-PD) and
BMD
I: 3 months, ↓ u-DPD,
u-PD; 6 months, ↑ BAP
and ↓ OC, u-DPD, u-PD;
9 months, ↓ u-DPD,
u-PD; 12 months, ↑ BAP
and ↓ OC, u-DPD, u-PD;
C: 3 months, ↓ OC,
u-DPD, u-PD; 6 months,
↑ BAP, u-DPD, u-PD
and ↓ OC; 9 months, ↑
u-DPD, u-PD and ↓ OC;
12 months, ↑ BAP,
u-DPD, u-PD and ↓ OC
BTM
I vs C: 3 months, ↓ u-DPD
BMD
I vs C: 12 months ↑
In postmenopausal women,
bone mass can be increased
significantly by K citrate. The
effect on bone resorption
seems to be unrelated to K
intake.
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Table 3. Cont.
Reference Study Design; Population
Intervention
(Dose/Day) (I)
Control (C)
Other
Supplements
(Dose/Day)
and/or
Controlled
Dietary Intake
Follow Up and
Outcomes
BTM Changes
(Intragroup)
Changes in BTM and BMD
Induced by Intervention
(Intergroup)
Conclusion
Macdonald, 2008
[134]
RCT, controlled vs. placebo,
double-blind for I1 e I2; ≥5
years postmenopausal
women; age: 49–54 years
I 1: K citrate (55.5 mEq),
n = 70
I 2: K citrate (18.5 mEq),
n = 70
I 3: Diet (300 g fruit =
18.5 mEq alkali), n = 66
C: Placebo, n = 70
Food diary (free
nonvegetarian
diet)
Baseline, 3, 6, 12, 18,
24 months;
BTM (CTX, P1NP,
u-DPD) and BMD
I 1: n.s.
I 2: n.s.
I 3: n.s.
C: n.s
BTM
I 1, I 2, I 3 vs. C: n.s
BMD
I 1, I 2, I 3 vs. C: n.s
In healthy postmenopausal
women, neither K citrate at
18.5 or 55.6 mEq/d, nor 300 g
self-selected fruit and
vegetables influenced bone
turnover or prevented BMD
loss over 2 years.
Thomas, 2008
[149]
RCT, crossover,
double-blind, 2 phases;
postmenopausal women for
2 to 6 years; age: 50–60
years
I 1: Ca carbonate (1000
mg Ca), n = 12
I 2: 2) Ca citrate (500 mg
Ca), n = 13
Controlled Ca
intake
Baseline, 7 days;
BTM (CTX)
I 1: 7 days, ↓ CTX
I 2: 7 days, ↓ CTX
Ca citrate is at least as
effective as Ca carbonate in
decreasing PTH and CTX
cross-links, at half the dose.
All changes are numerically
superior after Ca citrate
supplementation.
Karp, 2009 [140]
RCT, controlled, 24 h study
sessions; women of
child-bearing age: 22–30
years
I 1: Ca carbonate (1000
mg Ca), n = 12
I 2: Ca citrate (Ca: 1000
mg; citrate: 3145 mg), n
= 12
I 3: K citrate (K: 57 mEq;
citrate: 3145 mg), n = 12
4-day diary to
estimate food
habits before
starting the study
session; the meals
served during
each study session
were identical
Baseline, 2, 4, 6, 8, 20,
24 h;
BTM (BAP, u-NTX)
and BMD
I 1: 24 h, ↓ u-NTX
I 2: n.s
I 3: 24 h, ↓ u-NTX
K citrate supplementation
decreases urinary Ca
excretion and reduces bone
resorption even when the diet
is not acidogenic, and reduces
the bone resorption marker
despite low Ca intake.
Jehle, 2013 [150]
RCT, controlled vs. placebo,
double-blind;
healthy subjects (79 M/122
F); T score > −2.5; age 65–80
years; women were past the
perimenopausal peak
turnover
I: K citrate (60 mEq), n =
101
C: Placebo, n = 100
Ca carbonate (500
mg), Vitamin D3
(400 IU); free
nonvegetarian diet
Baseline, 6, 12, 18, 24;
BTM (BAP, P1NP,
u-NTX) and BMD
I: 6, 12 months, ↓ u-NTX;
18, 24 months, ↑ P1NP
C: n.s.
BTM
I vs. C: 6 months, ↓ u-NTX
BMD
I vs. C: 12, 18, 24 months ↑
K citrate administered in a
background of vitamin D and
Ca supplementation is well
tolerated and constitutes an
inexpensive intervention to
improve BMD and bone
microarchitecture in healthy
elderly people.
Moseley, 2013
[151]
RCT, controlled vs. placebo,
double blind;
healthy subjects (17 M/35 F);
age ≥ 55 years; women were
≥5 years postmenopause
I 1: K citrate (60 mmol),
n = 17
I 2: K citrate (90 mmol),
n = 17
C: Placebo, n = 18
Ca citrate (630 mg),
Vitamin D3 (400
IU); controlled Ca,
Na, P, protein, fat
intake
Baseline, 6 months;
BTM, (BAP, CTX)
BTM
I 1, I2 vs. C: 6 months, ↓ CTX
K citrate decreases markers of
bone resorption over 6
months, but a significant
improvement in Ca balance is
obtained with 90 mmol/day.
This dose is well tolerated.
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Table 3. Cont.
Reference Study Design; Population
Intervention
(Dose/Day) (I)
Control (C)
Other
Supplements
(Dose/Day)
and/or
Controlled
Dietary Intake
Follow Up and
Outcomes
BTM Changes
(Intragroup)
Changes in BTM and BMD
Induced by Intervention
(Intergroup)
Conclusion
Gregory, 2015
[152]
RCT, controlled vs. placebo,
double-blind;
≥2 year postmenopausal
women s; T score: <−1.0 >
−2.5, or <−2.5 unable to
take any other medication;
age I: 65.1 ± 5.9 years; C:
66.1 ± 7.1 years
I: K citrate (40 mEq), n =
42
C: Placebo, n = 41
Ca citrate (630 mg),
Vitamin D3 (400
IU); free
nonvegetarian diet
Baseline, 1, 3, 6, 12
months;
BTM (BAP, OC, P1NP,
u-NTX) and BMD
I: 1 month, ↓ P1NP; 3, 6,
12 months, ↓ P1NP,
u-NTX
C. I: 6 months, ↓ P1NP
u-NTX; 12 months, ↓
P1NP
BTM
I vs. C: n.s
BMD
I: 12 months, stable
In postmenopausal
osteopenia, K citrate improves
the effect of supplementation
with Ca citrate and Vitamin D,
as proven by the more rapid
decrease in BTM levels.
Granchi, 2018
[91]
RCT, controlled vs. placebo,
double-blind; ≥5 years
postmenopausal women; T
score: <−1.0 and >−2.5; age
I: 60.8 ± 1.0 years; C: 58.2 ±
1.1 years
I: K citrate (30 mEq), n =
20
C: Placebo, n = 20
Ca carbonate (500
mg), Vitamin D3
(400 IU); free
nonvegetarian diet
Baseline, 3, 6 months;
BTM (BAP, CTX,
P1NP, TRAcP)
I: 6 months, ↓ BAP, CTX
C: 3, 6 months, ↓ BAP,
CTX
BTM
I vs. C: 6 months ↓ BAP, CTX
in subjects with low excretion
of K and/or citrate, and/or low
urine pH
In postmenopausal
osteopenia, K citrate
improves the effects of
supplementation with Ca
carbonate and vitamin D, but
only in women with low K
and/or citrate excretion and/or
low urine pH.
C: control; I: Intervention; RCT: randomised clinical trial; K citrate: potassium citrate; Ca carbonate: calcium carbonate; Ca citrate: calcium citrate; KCl: potassium chloride; Na: sodium;
P: phosporus; BMD: bone mineral density; BTM: bone turnover markers; n.a.: not applicable; n.s.: not significant; BAP: bone-specific alkaline phosphatase; BMD: bone mineral density;
K: tpotassium; Ca: calcium; u-DPD: urinary deoxypyridinoline; u-PYR: urinary pyridinoline; u-OH proline: urinary hydroxyproline; OC: osteocalcin; P1NP: amino-terminal propeptide of
type 1 procollagen; u-NTX: urinary N-telopeptide of collagen type 1; M: male; F: female; IU: International Units; PTH: parathyroid hormone; ↓ and ↑ show significant decreases and
increases, respectively, according to the criteria indicated by the authors. * Partial data collected from the abstract.
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The authors investigated the effect of potassium citrate (one clinical trial, seven randomised clinical
trials (RCTs)) [92,134,139–144], calcium citrate (four RCTs and two crossover studies) [145–150], and two
studies compared the above-mentioned treatments (one RCT, one crossover study) [139,140]. Regarding
the intervention under investigation, doses, timing of administration, and follow-up varied greatly
among the trials and, in thirteen studies, the co-administration of additional supplements was planned,
i.e., calcium carbonate and/or vitamin D3. The majority of the studies included postmenopausal
women (n = 11) while, in one study, the participants were of childbearing age. The other trials were
designed to recruit healthy individuals, i.e., males and females at least 55 years of age. The dietary
intake of calcium and/or protein and/or salts was controlled in ten studies; in five studies, the subject
consumed a free nonvegetarian diet; in one study, the management of food habits was not described.
Overall, the studies selected provided more than 1000 experimental cases and more than
900 controls. As Lambert et al. reported previously, very high heterogeneity among the studies was
observed, and therefore the meta-analysis lost its inferential value while the descriptive overview
was more informative. By examining the conclusions reported by various authors, two recurring
key points emerged: (1) an adequate calcium intake was essential in preventing bone loss in elderly
subjects and in postmenopausal women, and calcium citrate seemed to be more effective than calcium
carbonate [145–150] and (2) potassium citrate prevented the increased bone resorption caused by
menopause, chronic acidemia and high salt intake [139–144].
Additional findings regarding potassiun citrate can be summarised as follows: effectiveness may
be enhanced by combined treatment with calcium citrate [139]; positive effects have also been observed
in young women and in the absence of an excessive acid load [140]. Moreover, supplementation with
alkalising potassium citrate improved the beneficial effects of calcium and vitamin D only in osteopenic
postmenopausal women who exhibited the target conditions, namely low potassium and/or citrate
excretion and/or low urine pH [91]. Finally, one study questioned the beneficial effects of potassium
citrate since, at 24 months, no significant modifications in BTMs and BMD were recorded [134].
It should be noted that compliance may decrease by 25% over time, mainly due to gastrointestinal side
effects (approximately 10%) and costs [24].
Despite the encouraging results, a consensus statement regarding the use of citrate supplementation
for the management of metabolic bone diseases is still lacking since the heterogeneity of the current
evidence is a major limitation for identifying the best practice. Interestingly, the identification of
subjects who better respond to exogenous citrate supplementation could be the correct way to maximise
the beneficial effect of the treatment.
6. Conclusions
Since citrate is a ubiquitous metabolite with a multidimensional role in the human organism, it is
not surprising that it is involved in the pathophysiology of tissues, organs and systems. In fact, recent
data in the literature have highlighted the relationship between citrate defects and various medical
conditions with considerable financial and social impact, e.g., cancer [153], dyslipidemia [154], vascular
calcifications [155], and visual disabilities [156].
Overall, this review has highlighted the main functions of citrate, and, more specifically, focused
on the role of citrate in the pathophysiology and medical management of metabolic bone diseases,
thus identifying some key points which are summarised in Table 4.
Although interest in the role of citrate is spreading, a consensus statement regarding the use
of citrate supplementation for the management of metabolic bone diseases is still lacking, since the
heterogeneity of the current evidence is a major limitation in identifying the best practice. Even when
the study design is well planned, there are some reasons which may explain the difficulty in obtaining
unique and compelling results from clinical trials.
First, dietary supplementation cannot be regarded as a pharmacological treatment, and therefore
the effects on measurable clinical outcomes are expected to be less prominent. Hence, baseline
differences between participants which are beyond the investigator’s control become selection biases
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that attenuate the strength of randomisation and interfere with the interpretation of the results. On the
other hand, current scientific knowledge provides a sufficient background, leading the clinician and
the researcher to further investigate the beneficial effects of citrate-based treatment in depth, as proven
by multiple studies which have dealt with this matter.
At present, it can be argued that the use of citrate supplementation should be considered in the
medical management of bone diseases, but it is also reasonable to assume that the effects could be
maximised in a personalised approach in which the scientific knowledge and the clinical judgement of
practitioners are essential in identifying patients who could reap real benefits.
Table 4. The role of citrate in the pathophysiology and medical management of bone diseases.
Highlights
• Citrate is an essential metabolite and plays a pivotal role in maintaining the acid-base balance.
• Citrate is an essential component of bone, and serves to maintain the integrity of the skeletal nano-
and microstructures.
• Citrate is produced by osteoblasts but, at the same time, it influences their differentiation and functionality.
• Bone tissue is the main source of citrate and is therefore a leading actor in maintaining citrate homeostasis.
• Citrate excretion is a significant biomarker of citrate homeostasis.
• Genetic and acquired diseases characterised by an alteration in citrate homeostasis are often accompanied
by alterations in the development and/or metabolism of bone tissue.
• Exogenous supplementation may be a useful tool in treating medical conditions related to poor citrate
bioavailability, including bone diseases.
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